Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

House dust mite allergy immunotherapy - ALK-Abello

Drug Profile

House dust mite allergy immunotherapy - ALK-Abello

Alternative Names: ACARIZAX; ALK HDM; ALK Mite Tablet; HDM AIT; HDM SLIT drops - ALK-Abello; HDM SLIT extract - ALK-Abello; HDM SLIT tablet- ALK-Abello; House dust mite extract - ALK-Abello; House dust mite SLIT drops - ALK-Abello; House dust mite SLIT One Dermatophagoides mixture - ALK-Abello; House dust mite SLIT tablet - ALK-Abello; MITICURE; Mitizax; MK-8237; Odactra; SCH-900237; SLITONEULTRA-HDM; SQ®HDM SLIT-tablet - ALK-Abello; TO-203

Latest Information Update: 02 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALK-Abello
  • Developer Abbott Laboratories; ALK-Abello; Merck & Co; Seqirus; Torii Pharmaceutical
  • Class Allergens; Allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic asthma; Allergic rhinitis; Allergic rhinoconjunctivitis
  • Phase III Atopic dermatitis; Rhinoconjunctivitis

Most Recent Events

  • 25 Jan 2024 Preregistration for Allergic rhinitis (In children) in European Union (Sublingual)
  • 25 Jan 2024 ALK-Abelló announces intention to submit BLA to US FDA for Allergic rhinitis (In children) (Sublingual, Tablet) in first half of 2024
  • 25 Jan 2024 ALK-Abello completes the phase III MATIC trial in Allergic rhinitis (In children) in USA, Bulgaria, Canada, France, Germany, Lithuania, Poland, Russia, Slovakia, Spain, Ukraine (Sublingual, Tablet) before January 2024 (NCT04145219)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top